시장보고서
상품코드
1485081

치쿤구니야열 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측, 진단별, 치료별, 최종 사용자별, 지역별, 경쟁사별(2019-2029년)

Chikungunya Fever Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Diagnosis, By Treatment, By End User, By Region and Competition, 2019-2029F

발행일: | 리서치사: TechSci Research | 페이지 정보: 영문 186 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    


■ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

치쿤구니야열 세계 시장은 2023년 4억 6,323만 달러로 평가되었고, 2029년까지 6.38%의 연평균 복합 성장률(CAGR)을 나타내며 예측 기간 동안 꾸준히 성장할 것으로 예상됩니다.

세계 치쿤구니야열 시장은 치쿤구니야 바이러스가 야기하는 문제를 해결하는 데 초점을 맞춘 헬스케어 및 제약 산업의 역동적인 부문입니다. 모기가 매개하는 이 바이러스성 질환은 급속한 확산과 심한 관절통, 발열, 발진 등 쇠약하게 만드는 증상으로 인해 최근 몇 년동안 많은 관심을 받고 있습니다. 이 시장에는 치쿤구니야 바이러스 감염을 예방하고 치료하기 위한 진단 도구, 치료제, 백신, 매개 모기 퇴치법 등 다양한 제품과 서비스가 포함되어 있습니다. 치쿤구니야열 시장의 큰 성장과 혁신은 몇 가지 중요한 요인에 의해 이루어졌습니다. 주요 요인 중 하나는 특히 열대 및 아열대 지역에서 치쿤구니야 감염증의 발생률 증가입니다. 이 질병에 대한 특정 항바이러스 치료제의 부재는 시장 확대에 더욱 박차를 가하고 있습니다. 진단 도구는 조기 발견과 정확한 진단에 필수적인 자산으로 부상하고 있으며, 신속한 환자 관리와 역학 감시를 용이하게 합니다.

시장 개요
예측 기간 2025-2029년
시장 규모 : 2023년 4억 6,323만 달러
시장 규모 : 2029년 6억 6,873만 달러
CAGR : 2024-2029년 6.38%
급성장 부문 혈청학적 검사
최대 시장 남미

진단제뿐만 아니라 치료제 및 백신 개발도 치쿤구니야열 시장의 중요한 축을 이루고 있습니다. 연구자들과 제약회사들은 항바이러스제 및 단클론 항체를 포함한 치쿤구니아열 치료제의 안전성과 효능을 평가하기 위한 임상시험에 적극적으로 참여하고 있습니다. 백신은 치쿤구니야 감염 예방에 특히 유망하며, 바이러스 확산을 억제하는 효과를 확인하기 위해 엄격한 시험이 진행되고 있습니다. 바이러스를 매개하는 모기의 수를 줄이는 데 중점을 둔 매개 모기 대책은 치쿤구니야열 시장의 또 다른 중요한 측면입니다. 이러한 대책에는 살충제, 유충 구제제 사용, 모기의 번식지 및 개체수 증가를 제한하기 위한 지역 기반 개입 등 다양한 전략이 포함됩니다. 매개체 통제 노력은 치쿤구니야의 감염을 억제하고 발병 위험을 줄이는 데 중요한 역할을 하고 있습니다.

이해관계자들이 바이러스에 대한 대응을 계속하는 가운데, 치쿤구니야열 시장은 더 큰 성장과 혁신을 이룰 준비가 되어 있습니다. 현재 진행 중인 연구 개발 및 공동 연구는 치쿤구니야열 진단, 치료제, 백신, 매개 모기 퇴치 방법에 대한 새로운 지식을 제공할 것으로 기대됩니다. 전 세계의 노력으로 의료 및 제약 업계는 치쿤구니야열 퇴치에 큰 진전을 이룰 수 있으며, 궁극적으로 공중보건 성과를 개선하고 모기 매개 질환의 부담을 줄일 수 있을 것입니다.

시장 성장 촉진요인

치쿤구니아우식증 발병률 증가

진단의 발전

특이적 치료법의 부족

주요 시장 과제

조사 자금 부족

진단의 복잡성

주요 시장 동향

백신 개발의 진전

벡터 제어 전략

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 세계의 치쿤구니야열 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 진단별(ELISA 기반 어세이, 혈청학적 검사, 바이러스학적 검사)
    • 치료별(대증요법, 동종의학, 아유르베다, 기타)
    • 최종사용자별(병원 및 진료소, 외래 외과, 기타)
    • 지역별
    • 기업별(2023년)
  • 시장 맵
    • 진단별
    • 치료별
    • 최종사용자별
    • 지역별

제5장 아시아태평양의 치쿤구니야열 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 진단별
    • 치료별
    • 최종사용자별
    • 국가별
  • 아시아태평양 : 국가별 분석
    • 중국
    • 인도
    • 호주
    • 일본
    • 한국

제6장 유럽의 치쿤구니야열 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 진단별
    • 치료별
    • 최종사용자별
    • 국가별
  • 유럽 : 국가별 분석
    • 프랑스
    • 독일
    • 스페인
    • 이탈리아
    • 영국

제7장 북미의 치쿤구니야열 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 진단별
    • 치료별
    • 최종사용자별
    • 국가별
  • 북미 : 국가별 분석
    • 미국
    • 멕시코
    • 캐나다

제8장 남미의 치쿤구니야열 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 진단별
    • 치료별
    • 최종사용자별
    • 국가별
  • 남미 : 국가별 분석
    • 브라질
    • 아르헨티나
    • 콜롬비아

제9장 중동 및 아프리카의 치쿤구니야열 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 진단별
    • 치료별
    • 최종사용자별
    • 국가별
  • 중동 및 아프리카 : 국가별 분석
    • 남아프리카공화국
    • 사우디아라비아
    • 아랍에미리트(UAE)

제10장 시장 역학

  • 성장 촉진요인
  • 과제

제11장 시장 동향과 발전

  • 최근 동향
  • 제품 출시
  • 인수합병(M&A)

제12장 세계의 치쿤구니야열시장 : SWOT 분석

제13장 Porter의 Five Forces 분석

  • 업계내 경쟁
  • 신규 참여 가능성
  • 공급업체의 힘
  • 고객의 힘
  • 대체품의 위협

제14장 경쟁 구도

  • Quest Diagnostics, Inc.
  • Abbott Laboratories, Inc.
  • Genome Diagnostics Pvt. Ltd.
  • Altona Diagnostics GmbH
  • Bio-Rad Laboratories, Inc.
  • Taj Pharmaceuticals Ltd.
  • Etubics Corporation

제15장 전략적 제안

제16장 리서치사에 대해 & 면책사항

LSH 24.06.04

Global Chikungunya Fever Market was valued at USD 463.23 Million in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 6.38% through 2029. The global Chikungunya Fever market is a dynamic sector within the healthcare and pharmaceutical industry, dedicated to addressing the challenges posed by the Chikungunya virus. This mosquito-borne viral disease has garnered attention in recent years due to its rapid spread and debilitating symptoms, such as severe joint pain, fever, and rash. The market encompasses various products and services, including diagnostic tools, therapeutics, vaccines, and vector control methods, all aimed at both preventing and treating Chikungunya virus infections. Significant growth and innovation characterize the Chikungunya Fever market, driven by several key factors. One of the primary drivers is the increasing incidence of Chikungunya outbreaks, particularly in tropical and subtropical regions. The lack of specific antiviral treatments for the disease has further fueled market expansion. Diagnostic tools have emerged as indispensable assets in early detection and accurate diagnosis, facilitating prompt patient management and epidemiological surveillance.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 463.23 Million
Market Size 2029USD 668.73 Million
CAGR 2024-20296.38%
Fastest Growing SegmentSerological Tests
Largest MarketSouth America

Beyond diagnostics, the development of therapeutics and vaccines stands as a critical pillar of the Chikungunya Fever market. Researchers and pharmaceutical companies are actively involved in clinical trials to assess the safety and efficacy of potential Chikungunya treatments, including antiviral drugs and monoclonal antibodies. Vaccines hold particular promise in preventing Chikungunya infections and are undergoing rigorous testing to ascertain their effectiveness in controlling the virus's spread. Vector control measures constitute another essential aspect of the Chikungunya Fever market, focusing on reducing mosquito populations responsible for transmitting the virus. These measures encompass a range of strategies, including the use of insecticides, larvicides, and community-based interventions aimed at limiting mosquito breeding sites and population growth. Vector control efforts play a vital role in curbing Chikungunya transmission and mitigating the risk of outbreaks.

The Chikungunya Fever market is poised for further growth and innovation as stakeholders continue to address the challenges posed by the virus. Ongoing research, development, and collaboration efforts are expected to yield new insights into Chikungunya diagnostics, therapeutics, vaccines, and vector control methods. With a concerted global effort, the healthcare and pharmaceutical industry is well-positioned to make significant strides in combating Chikungunya fever, ultimately improving public health outcomes and reducing the burden of this mosquito-borne disease.

Key Market Drivers

Rising Incidence of Chikungunya

The rising incidence of Chikungunya is a key driver fueling the growth of the global Chikungunya Fever market. Chikungunya fever, caused by the Chikungunya virus and transmitted by Aedes mosquitoes, has become a significant public health concern due to its rapid global expansion. Climate change increased international travel, and urbanization have all contributed to the wider geographic spread of the disease, leading to more frequent and larger-scale outbreaks.

This growing burden of Chikungunya has created a sense of urgency and has spurred investments in research, development, and innovation across various sectors of the Chikungunya Fever market. Healthcare professionals, researchers, and pharmaceutical companies are increasingly focusing on addressing the challenges posed by this mosquito-borne viral disease. Diagnostic tools, therapeutics, vaccines, and vector control methods have all seen heightened interest and development in response to the rising incidence of Chikungunya. The need for better Chikungunya prevention, diagnosis, and treatment is evident, and this surge in demand is driving market growth. Efforts to develop more accurate diagnostic tests, effective antiviral treatments, and promising vaccine candidates have gained momentum. Additionally, innovative vector control strategies aimed at reducing mosquito populations responsible for transmitting the virus are being explored to mitigate the risk of outbreaks.

The escalating incidence of Chikungunya represents a critical market driver, compelling stakeholders to take action and invest in solutions that will help combat the disease. With continued research and development efforts, the global Chikungunya Fever market is positioned to make a significant impact in reducing the prevalence and impact of Chikungunya fever on a global scale.

Diagnostic Advancements

Diagnostic advancements are playing a pivotal role in boosting the global Chikungunya Fever market. Accurate and timely diagnosis of Chikungunya is crucial for effective patient management and public health surveillance. Traditional diagnostic methods, such as serological assays, have limitations in terms of sensitivity and specificity, often leading to false-negative results and delayed confirmation of infection. However, recent advances in diagnostic technologies have transformed the landscape of Chikungunya diagnosis, enhancing both speed and accuracy.

One of the most significant breakthroughs has been the adoption of nucleic acid tests, such as polymerase chain reaction (PCR) and loop-mediated isothermal amplification (LAMP) assays. These molecular techniques have revolutionized Chikungunya diagnosis by allowing for the direct detection of the virus's genetic material in patient samples. They offer a higher level of sensitivity and specificity compared to traditional methods, making early and accurate diagnosis a reality. This is especially important because Chikungunya shares clinical symptoms with other arboviral diseases, and a precise diagnosis ensures the appropriate treatment and public health response. Point-of-care testing (POCT) devices and rapid diagnostic kits have become more accessible and efficient. These tools enable healthcare providers to diagnose Chikungunya at the patient's bedside, reducing the time required for confirmation and immediate treatment initiation. POCT devices have been particularly valuable in resource-limited settings where access to advanced laboratory facilities may be limited.

The incorporation of serological assays and nucleic acid tests into routine diagnostic protocols has significantly improved the detection and surveillance of Chikungunya outbreaks. As a result, healthcare professionals and public health agencies can respond more effectively to the disease, implementing control measures and reducing its spread.

Lack of Specific Treatments

The lack of specific antiviral treatments for Chikungunya fever is a major driver fueling the growth of the global Chikungunya Fever market. Chikungunya, caused by the Chikungunya virus, is characterized by debilitating symptoms, including severe joint pain, fever, and rash, and in some cases, it can lead to chronic joint complications that persist for months or even years. With no approved antiviral drugs specifically designed to treat Chikungunya, the disease has presented a significant medical challenge, motivating researchers, healthcare professionals, and pharmaceutical companies to address this treatment gap.

Pharmaceutical companies and research institutions have taken on the task of discovering and developing potential therapeutics to combat Chikungunya. These efforts have led to the investigation of antiviral drugs and monoclonal antibodies, among other treatment modalities. Clinical trials are actively underway to evaluate the safety and efficacy of these potential treatments, with the goal of providing healthcare providers with effective tools to manage severe Chikungunya cases, alleviate symptoms, and reduce the risk of long-term complications.

The absence of specific treatments has created a compelling market demand for Chikungunya therapeutics, as the need to alleviate patient suffering and enhance the quality of life for those affected by the disease becomes increasingly apparent. Pharmaceutical companies are investing in research and development, with the prospect of bringing novel treatments to the market.

Key Market Challenges

Limited Funding for Research

Limited funding for research is a significant hindrance to the growth and progress of the Global Chikungunya Fever Market. Chikungunya fever, a debilitating mosquito-borne viral disease, has garnered increased attention in recent years due to its rapid spread and the severity of its symptoms, which can persist for an extended period. Despite its growing global impact, Chikungunya research remains underfunded compared to other infectious diseases of similar significance. One of the primary reasons for limited funding is the competition for resources within the broader healthcare and research landscape. Diseases like HIV/AIDS, malaria, and tuberculosis receive a considerable share of funding due to their well-established global burdens and the substantial efforts to combat them. As a result, Chikungunya, although a significant public health concern, often struggles to secure the necessary financial support to drive research, innovation, and the development of preventive measures and treatments.

Developing an effective Chikungunya vaccine is a time-consuming and expensive process. Limited funding can slow down vaccine research, delay clinical trials, and hinder progress towards a licensed vaccine. This, in turn, affects the ability to prevent Chikungunya outbreaks effectively. Limited funding for drug development hampers efforts to discover and test potential antiviral treatments for Chikungunya. The absence of specific drugs to alleviate symptoms and reduce the duration of the illness can significantly impact patients' quality of life and the ability to manage severe cases. Effective mosquito control strategies, another vital component of Chikungunya prevention, require investment in research. Funding limitations can impede efforts to study and implement innovative vector control measures, including those addressing mosquito resistance to insecticides.

Diagnostic Complexities

Diagnostic complexities are significant obstacles hindering the growth and effectiveness of the Global Chikungunya Fever Market. Chikungunya fever, caused by the Chikungunya virus and transmitted by Aedes mosquitoes, is a viral illness characterized by symptoms such as high fever, severe joint pain, and skin rash. However, diagnosing Chikungunya accurately poses several challenges, which impact patient care and public health response. One of the primary diagnostic complexities is the overlap of symptoms between Chikungunya and other arboviral diseases, such as Dengue and Zika. These diseases often share clinical features, making it difficult to differentiate between them based solely on symptoms. As a result, misdiagnosis or delayed confirmation of Chikungunya is not uncommon, leading to potential treatment delays and hampering effective epidemiological surveillance.

Traditional diagnostic methods, like serological assays, have limitations in sensitivity and specificity. They may yield false-negative or false-positive results, further complicating the diagnostic process. Cross-reactivity with related viruses, such as Dengue, can lead to false-positive Chikungunya test results, requiring additional confirmatory testing and potentially causing anxiety and confusion for patients.

Key Market Trends

Advancements in Vaccine Development

Advancements in vaccine development are playing a pivotal role in boosting the Global Chikungunya Fever Market. Chikungunya fever, caused by the Chikungunya virus and transmitted by Aedes mosquitoes, has been a growing public health concern due to its widespread global prevalence and debilitating symptoms. The development of a safe and effective Chikungunya vaccine has been a significant priority in the battle against the disease, and recent advancements in this field are driving the market forward.

Vaccine development for Chikungunya has seen remarkable progress in recent years, with several vaccine candidates entering preclinical and clinical trials. These candidates employ diverse strategies, including live-attenuated vaccines and virus-like particle (VLP) vaccines, all aimed at stimulating a protective immune response without causing the disease itself. These vaccine candidates have shown promising results in terms of safety and efficacy, offering hope for an effective preventive measure against Chikungunya.

The prospect of a licensed Chikungunya vaccine holds great promise for public health. Such a vaccine could substantially reduce the incidence of Chikungunya fever, preventing outbreaks and alleviating the burden on healthcare systems. It would not only improve patient outcomes but also limit the economic and social impact of the disease, particularly in regions where Chikungunya is endemic. The development of a Chikungunya vaccine showcases the potential for innovation in the broader field of infectious disease prevention. These advancements in vaccine development can inform strategies for combating other mosquito-borne viral diseases, ultimately contributing to improved global public health preparedness. As vaccine candidates progress through clinical trials and regulatory approval processes, the Chikungunya Fever Market is expected to see further growth and investments. The focus on vaccine development provides a promising pathway to effectively control Chikungunya and reduce its impact on individuals and communities worldwide.

Vector Control Strategies

Vector control strategies are playing a significant role in boosting the Global Chikungunya Fever Market. Chikungunya fever, caused by the Chikungunya virus and transmitted by Aedes mosquitoes, has emerged as a considerable global health concern. Vector control measures aim to mitigate the risk of Chikungunya transmission by reducing the mosquito population responsible for carrying and spreading the virus. Recent advancements in these strategies have led to notable progress within the Chikungunya Fever Market.

Traditionally, vector control methods included the use of insecticides and larvicides to target mosquito breeding sites. While these measures have been effective to some extent, challenges such as mosquito resistance to chemicals and the need for sustainable solutions have prompted the development of innovative approaches. One such approach involves the use of genetically modified mosquitoes to reduce the Aedes mosquito population. By releasing genetically altered male mosquitoes, which do not transmit the virus, into the environment, they can mate with wild female mosquitoes, leading to non-viable offspring. This strategy helps lower mosquito numbers, ultimately reducing the risk of Chikungunya transmission.

Another emerging trend in vector control strategies involves the use of Wolbachia-infected mosquitoes. Wolbachia is a naturally occurring bacterium that, when introduced into Aedes mosquitoes, hinders their ability to transmit the Chikungunya virus. Such Wolbachia-infected mosquito releases have demonstrated success in field trials, contributing to a reduced risk of Chikungunya transmission. Community-based interventions, including education and awareness programs, have also gained prominence as a key vector control strategy. These initiatives empower communities to eliminate mosquito breeding sites, manage water storage containers, and use bed nets and protective clothing, reducing their exposure to Aedes mosquitoes. Such community-driven efforts are essential in regions where resources are limited and local participation is crucial for successful vector control.

Segmental Insights

Diagnosis Insights

Based on Diagnosis, Serological tests emerged as the fastest growing segment in the Global Chikungunya Fever Market in 2023. Serological tests are highly accurate and specific for Chikungunya. They detect the presence of IgM and IgG antibodies produced by the patient's immune system in response to Chikungunya infection. These antibodies typically become detectable in the blood within a few days to a week after the onset of symptoms. This accuracy is crucial for timely and reliable diagnosis. Serological tests can be used for both acute and convalescent-phase testing. This means that they are valuable not only for diagnosing current Chikungunya infections but also for confirming past infections, even after the acute phase of the disease has passed. This retroactive testing is significant for understanding the disease's epidemiology. Serological tests are relatively cost-effective, making them a practical choice for large-scale screening and surveillance efforts. They are particularly useful in areas where resources may be limited, and cost considerations play a crucial role in test selection.

Treatment Insights

Based on Treatment, Allopathy emerged as the dominant segment in the Global Chikungunya Fever Market in 2023. Allopathic treatments for Chikungunya primarily focus on relieving the symptoms and managing the pain and discomfort associated with the disease. Nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and paracetamol are commonly used to reduce fever, pain, and inflammation. These medications have a proven track record of efficacy in providing symptomatic relief to Chikungunya patients. Allopathy is the dominant and widely accepted system of medicine around the world. Healthcare professionals, including physicians and nurses, are extensively trained in allopathic medicine, and this system is the foundation of healthcare systems in many countries. The familiarity and trust associated with allopathy make it the first choice for both patients and healthcare providers.

Regional Insights

Based on region, South America has emerged as a dominant region in the Global Chikungunya Fever Market in 2023 due to several key factors contributing to its prominence in the fight against the Chikungunya virus. One of the primary reasons is the region's susceptibility to Chikungunya outbreaks, driven by favorable climatic conditions and the presence of the Aedes mosquitoes, which serve as vectors for the virus. South American countries, particularly those in tropical and subtropical regions, experience high incidences of Chikungunya fever, making the market for diagnostic tools, therapeutics, and vector control measures highly active and dynamic. The proactive response of South American governments and healthcare authorities to Chikungunya outbreaks has played a crucial role in establishing the region as a dominant market. These entities have implemented robust surveillance systems, public awareness campaigns, and vector control programs to mitigate the impact of Chikungunya fever and prevent further transmission of the virus. South America has witnessed significant investments in research and development efforts aimed at developing diagnostics, therapeutics, and vaccines tailored to the unique challenges posed by Chikungunya outbreaks in the region.

Collaborations between South American healthcare institutions, research organizations, and pharmaceutical companies have fostered innovation and accelerated the development and deployment of novel solutions to combat Chikungunya fever. These collaborations have facilitated the sharing of expertise, resources, and best practices, resulting in the rapid advancement of diagnostic and therapeutic interventions for Chikungunya virus infections. The growing awareness of Chikungunya fever among healthcare professionals, policymakers, and the general public in South America has also contributed to the region's dominance in the global market. With increasing recognition of the socioeconomic impact of Chikungunya outbreaks on communities and healthcare systems, there has been a heightened focus on investing in preventive measures and innovative solutions to address the evolving challenges posed by the virus. South America's proactive approach to Chikungunya fever management, coupled with investments in research, public health infrastructure, and collaborative initiatives, has positioned the region as a key player in the global market for Chikungunya Fever solutions. As Chikungunya outbreaks continue to pose significant public health challenges worldwide, South America's leadership and expertise in combating the virus are likely to remain pivotal in shaping the future of the Chikungunya Fever market.

Key Market Players

Quest Diagnostics, Inc.

Abbott Laboratories, Inc.

Genome Diagnostics Pvt. Ltd.

Altona Diagnostics GmbH

Bio-Rad Laboratories, Inc.

Taj Pharmaceuticals Ltd.

Etubics Corporation

Report Scope:

In this report, the Global Chikungunya Fever Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Chikungunya Fever Market, By Diagnosis:

    ELISA Based Assays Serological Tests Virological Tests

Chikungunya Fever Market, By Treatment:

    Allopathy Homeopathy Ayurveda Others

Chikungunya Fever Market, By End User:

    Hospital & Clinics Ambulatory Surgical care Others

Chikungunya Fever Market, By Region:

    North America

United States

Canada

Mexico

    Europe

France

United Kingdom

Italy

Germany

Spain

    Asia Pacific

China

India

Japan

Australia

South Korea

    South America

Brazil

Argentina

Colombia

    Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Chikungunya Fever Market.

Available Customizations:

Global Chikungunya Fever Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Chikungunya Fever Market Outlook

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share & Forecast
    • 4.2.1. By Diagnosis (ELISA Based Assays, Serological Tests, Virological Tests)
    • 4.2.2. By Treatment (Allopathy, Homeopathy, Ayurveda, Others)
    • 4.2.3. By End User (Hospital & Clinics, Ambulatory Surgical care, Others)
    • 4.2.4. By Region
    • 4.2.5. By Company (2023)
  • 4.3. Market Map
    • 4.3.1. By Diagnosis
    • 4.3.2. By Treatment
    • 4.3.3. By End User
    • 4.3.4. By Region

5. Asia Pacific Chikungunya Fever Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Diagnosis
    • 5.2.2. By Treatment
    • 5.2.3. By End User
    • 5.2.4. By Country
  • 5.3. Asia Pacific: Country Analysis
    • 5.3.1. China Chikungunya Fever Market Outlook
      • 5.3.1.1. Market Size & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share & Forecast
        • 5.3.1.2.1. By Diagnosis
        • 5.3.1.2.2. By Treatment
        • 5.3.1.2.3. By End User
    • 5.3.2. India Chikungunya Fever Market Outlook
      • 5.3.2.1. Market Size & Forecast
        • 5.3.2.1.1. By Value
      • 5.3.2.2. Market Share & Forecast
        • 5.3.2.2.1. By Diagnosis
        • 5.3.2.2.2. By Treatment
        • 5.3.2.2.3. By End User
    • 5.3.3. Australia Chikungunya Fever Market Outlook
      • 5.3.3.1. Market Size & Forecast
        • 5.3.3.1.1. By Value
      • 5.3.3.2. Market Share & Forecast
        • 5.3.3.2.1. By Diagnosis
        • 5.3.3.2.2. By Treatment
        • 5.3.3.2.3. By End User
    • 5.3.4. Japan Chikungunya Fever Market Outlook
      • 5.3.4.1. Market Size & Forecast
        • 5.3.4.1.1. By Value
      • 5.3.4.2. Market Share & Forecast
        • 5.3.4.2.1. By Diagnosis
        • 5.3.4.2.2. By Treatment
        • 5.3.4.2.3. By End User
    • 5.3.5. South Korea Chikungunya Fever Market Outlook
      • 5.3.5.1. Market Size & Forecast
        • 5.3.5.1.1. By Value
      • 5.3.5.2. Market Share & Forecast
        • 5.3.5.2.1. By Diagnosis
        • 5.3.5.2.2. By Treatment
        • 5.3.5.2.3. By End User

6. Europe Chikungunya Fever Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Diagnosis
    • 6.2.2. By Treatment
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. Europe: Country Analysis
    • 6.3.1. France Chikungunya Fever Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Diagnosis
        • 6.3.1.2.2. By Treatment
        • 6.3.1.2.3. By End User
    • 6.3.2. Germany Chikungunya Fever Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Diagnosis
        • 6.3.2.2.2. By Treatment
        • 6.3.2.2.3. By End User
    • 6.3.3. Spain Chikungunya Fever Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Diagnosis
        • 6.3.3.2.2. By Treatment
        • 6.3.3.2.3. By End User
    • 6.3.4. Italy Chikungunya Fever Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Diagnosis
        • 6.3.4.2.2. By Treatment
        • 6.3.4.2.3. By End User
    • 6.3.5. United Kingdom Chikungunya Fever Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Diagnosis
        • 6.3.5.2.2. By Treatment
        • 6.3.5.2.3. By End User

7. North America Chikungunya Fever Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Diagnosis
    • 7.2.2. By Treatment
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Chikungunya Fever Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Diagnosis
        • 7.3.1.2.2. By Treatment
        • 7.3.1.2.3. By End User
    • 7.3.2. Mexico Chikungunya Fever Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Diagnosis
        • 7.3.2.2.2. By Treatment
        • 7.3.2.2.3. By End User
    • 7.3.3. Canada Chikungunya Fever Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Diagnosis
        • 7.3.3.2.2. By Treatment
        • 7.3.3.2.3. By End User

8. South America Chikungunya Fever Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Diagnosis
    • 8.2.2. By Treatment
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. South America: Country Analysis
    • 8.3.1. Brazil Chikungunya Fever Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Diagnosis
        • 8.3.1.2.2. By Treatment
        • 8.3.1.2.3. By End User
    • 8.3.2. Argentina Chikungunya Fever Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Diagnosis
        • 8.3.2.2.2. By Treatment
        • 8.3.2.2.3. By End User
    • 8.3.3. Colombia Chikungunya Fever Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Diagnosis
        • 8.3.3.2.2. By Treatment
        • 8.3.3.2.3. By End User

9. Middle East and Africa Chikungunya Fever Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Diagnosis
    • 9.2.2. By Treatment
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. MEA: Country Analysis
    • 9.3.1. South Africa Chikungunya Fever Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Diagnosis
        • 9.3.1.2.2. By Treatment
        • 9.3.1.2.3. By End User
    • 9.3.2. Saudi Arabia Chikungunya Fever Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Diagnosis
        • 9.3.2.2.2. By Treatment
        • 9.3.2.2.3. By End User
    • 9.3.3. UAE Chikungunya Fever Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Diagnosis
        • 9.3.3.2.2. By Treatment
        • 9.3.3.2.3. By End User

10. Market Dynamics

  • 10.1. Drivers
  • 10.2. Challenges

11. Market Trends & Developments

  • 11.1. Recent Developments
  • 11.2. Product Launches
  • 11.3. Mergers & Acquisitions

12. Global Chikungunya Fever Market: SWOT Analysis

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Product

14. Competitive Landscape

  • 14.1. Quest Diagnostics, Inc.
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (In case of listed)
    • 14.1.5. Recent Developments
    • 14.1.6. SWOT Analysis
  • 14.2. Abbott Laboratories, Inc.
  • 14.3. Genome Diagnostics Pvt. Ltd.
  • 14.4. Altona Diagnostics GmbH
  • 14.5. Bio-Rad Laboratories, Inc.
  • 14.6. Taj Pharmaceuticals Ltd.
  • 14.7. Etubics Corporation

15. Strategic Recommendations

16. About Us & Disclaimer

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제